| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1b8cce33ca2a4437640cb31e27fdcc2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6aed1838d2bab156022a7bb336798a56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0059941ff1c12d1d6d1b0cfcfa6e172f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a933a0dd561e3e50b278738704d5c6e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec7aa9366c4867ba95ac5cd4fbbaec25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_934ca69ede25389914cc7523e73055c1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-319
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3181
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-317 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
1999-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50376c7a9908de927d4640a44baa3e99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e098642527a6ced7c885e7751248b44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fa584eeb306bf6e91105cc828221d86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce511bcddf175c16ea3fbb2b16449ea9 |
| publicationDate |
2000-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0014219-A9 |
| titleOfInvention |
Peptide nucleic acid-oligoadenylate chimeric molecules |
| abstract |
Covalent conjugation of a 5'-phosphorylated-2',5'-linked oligoadenylate (2-5A) moiety to an antisense peptide nucleic acid oligomer (PNA) provides a novel chimeric reagent which effects the selective and specific cleavage of a selected target RNA. The 2-5A-antisense PNA chimeras bind the target RNA with high specificity and affinity, and are stable to nucleases. The antisense portion of the chimera recruits a chosen RNA as substrate for cleavage, and the 2-5A portion of the chimera binds and activates RNase L, thus providing a new approach for the targeted ablation of a target mRNA and a reduction in expression of the protein which it specifies. The chimeric molecules are expected to have utility as research tools and as therapeutic agents. |
| priorityDate |
1998-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |